ASCEND, Accelerating Solutions for Commercialization and Entrepreneurial Development in the Mountain West IDeA States

ASCEND,加速西部山区 IDeA 州的商业化和创业发展解决方案

基本信息

  • 批准号:
    9621296
  • 负责人:
  • 金额:
    $ 50万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-01 至 2019-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary The objective of this proposal is to create a Mountain West region technology Accelerator Hub to conduct research on developing, implementing, and testing a comprehensive collateral and consulting offering for promoting biomedical entrepreneurship, technology transfer, management, small business finance, and additional business skills needed to commercialize basic research to enhance human health. Many limiting factors hamper the ultimate goal of commercializing basic and translational science in IDeA states, including a gap in funding between basic research discoveries and scientific feasibility or validation studies required to define a product for early stage technology development, a lack of knowledge and understanding by innovators about how technologies are brought to market, a lack of access to sufficient technology development and commercialization resources for early-stage technology development, limited resources in Technology Transfer and Commercialization Offices, an insufficient number of local technology businesses to create a critical mass of entrepreneurial expertise and culture; a lack of exposure to commercialization education, training, and mentoring (including in patents, startups, business plans, venture capital and angel investing), a limited knowledge of technology transfer and SBIR/STTR programs; and a lack of awareness of available resources at the local, state and regional levels. To address these goals, we propose to create a regional technology Accelerator Hub throughout the Mountain West (Western) region of IDeA states that is closely networked with Mountain West IDeA state universities and their affiliated Technology Transfer Offices and small business partners. This network will provide the framework for effective communication and outreach that will create institutional change and build an entrepreneurial culture throughout this region. We will provide robust education and training of students and researchers and other entrepreneurs to accelerate development of commercialization activities, substantially increasing SBIR/STTR applications and facilitating communication between the NIH and IDeA institutions. The objectives of this application are to: 1) establish infrastructure, develop educational materials (curricula, texts, webinars, workshops and courses), and train staff; 2) accelerate entrepreneurialism through innovator mentoring, SBIR/STTR application submission, and increased partnering activity; 3) increase visibility of technological advancements, industry partnerships and licensing revenues through outreach, coaching and partnering activities, at each of the Mountain West IDeA state institutions. The product of this work will be the ASCEND solution, a comprehensive, sustainable educational and consulting services offering that will be leveraged across the Mountain West IDeA States-collaborating biomedical institutions and marketed to other institutions that want to accelerate biomedical entrepreneurship, thus ensuring the long-term sustainability, dissemination, and impact of this program.
项目摘要 该提案的目的是创建一个山区西部地区技术加速器中心,以进行 研究开发,实施和测试全面的抵押品和咨询产品的研究 促进生物医学企业家精神,技术转移,管理,小型企业融资和 将基础研究商业化以增强人类健康所需的其他业务技能。 许多限制因素妨碍了在思想中商业化基础和转化科学的最终目标 国家,包括基础研究发现与科学可行性或验证之间的资金差距 为早期技术开发定义产品所需的研究,缺乏知识和 创新者了解技术如何进入市场,缺乏足够的渠道 早期技术开发的技术开发和商业化资源,有限 技术转移和商业化办公室中的资源,这是一项不可能的本地技术 企业创建大量的企业家专业知识和文化;缺乏接触 商业化教育,培训和心理(包括专利,初创企业,商业计划,风险投资 Capital和Angel Investing),对技术转移和SBIR/STTR计划的有限知识;缺乏 在本地,州和地区级别的可用资源的认识。 为了解决这些目标,我们建议在整个山上创建一个区域技术加速器中心 西部(西部)思想国家与山区构思州立大学紧密建立联系 他们的会员技术转让办公室和小型企业合作伙伴。该网络将提供 有效沟通和宣传的框架,这些框架将创造机构变革并建立 整个地区的创业文化。我们将对学生提供强大的教育和培训 研究人员和其他企业家可以加速商业化活动的发展 增加SBIR/STTR应用程序,并支持NIH与Idea Instications之间的沟通。 该应用程序的目标是:1)建立基础设施,开发教育材料(课程, 文本,网络研讨会,研讨会和课程)和培训员工; 2)通过创新者加速企业家主义 心理,SBIR/STTR申请提交和增加合作活动; 3)提高可见度 技术进步,行业合作伙伴关系和许可通过外展,教练和 在每个山区构思州立机构的伙伴活动中。 这项工作的产物将是Ascend解决方案,这是一种全面,可持续的教育和 咨询服务产品将在山区构想国家范围内利用 生物医学机构,并向其他想要加速生物医学企业家精神的机构销售 从而确保该计划的长期可持续性,传播和影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Neil A Fanger其他文献

Neil A Fanger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Neil A Fanger', 18)}}的其他基金

A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection
预防淋病奈瑟菌感染的新型舌下疫苗
  • 批准号:
    10699065
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease
一种促进神经元完整性和神经发生的新型抗体,用于治疗阿尔茨海默病
  • 批准号:
    10721794
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis
一种治疗特发性肺纤维化的新型双特异性抗体
  • 批准号:
    10594937
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease
一种促进神经元完整性和神经发生的新型抗体,用于治疗阿尔茨海默病
  • 批准号:
    10600796
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
A Novel Small Molecule for the Treatment of Periodontitis
一种治疗牙周炎的新型小分子
  • 批准号:
    10481054
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis
一种治疗特发性肺纤维化的新型双特异性抗体
  • 批准号:
    10482438
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease
一种促进神经元完整性和神经发生的新型抗体,用于治疗阿尔茨海默病
  • 批准号:
    10706541
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease
一种促进神经元完整性和神经发生的新型抗体,用于治疗阿尔茨海默病
  • 批准号:
    10893118
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease
用于早期检测阿尔茨海默病的新型多参数血液测试
  • 批准号:
    10570790
  • 财政年份:
    2021
  • 资助金额:
    $ 50万
  • 项目类别:
A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease
一种用于早期检测阿尔茨海默病的新型多参数血液测试
  • 批准号:
    10491891
  • 财政年份:
    2021
  • 资助金额:
    $ 50万
  • 项目类别:

相似海外基金

Characterizing the genetic etiology of delayed puberty with integrative genomic techniques
利用综合基因组技术表征青春期延迟的遗传病因
  • 批准号:
    10663605
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
Social Vulnerability, Sleep, and Early Hypertension Risk in Younger Adults
年轻人的社会脆弱性、睡眠和早期高血压风险
  • 批准号:
    10643145
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
ACTS (AD Clinical Trial Simulation): Developing Advanced Informatics Approaches for an Alzheimer's Disease Clinical Trial Simulation System
ACTS(AD 临床试验模拟):为阿尔茨海默病临床试验模拟系统开发先进的信息学方法
  • 批准号:
    10753675
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
Unraveling how Lipophilic Modulators Alter pLGIC Function via Interactions with the M4 Transmembrane Helix
揭示亲脂性调节剂如何通过与 M4 跨膜螺旋相互作用改变 pLGIC 功能
  • 批准号:
    10785755
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
Testing Approaches to Promote Breast Cancer Screening in Rural Ghana
促进加纳农村地区乳腺癌筛查的测试方法
  • 批准号:
    10645446
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了